These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 22141602)
1. Imaging characteristics of extrapulmonary tuberculosis lesions on dual time point imaging (DTPI) of FDG PET/CT. Razak HR; Geso M; Abdul Rahim N; Nordin AJ J Med Imaging Radiat Oncol; 2011 Dec; 55(6):556-62. PubMed ID: 22141602 [TBL] [Abstract][Full Text] [Related]
2. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
3. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases]. Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458 [TBL] [Abstract][Full Text] [Related]
4. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin. Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438 [TBL] [Abstract][Full Text] [Related]
5. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Collins DA; Kasperbauer JL; Strome SE; Reading CC; Hay ID; Lowe VJ Nucl Med Commun; 2007 May; 28(5):373-81. PubMed ID: 17414887 [TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET and PET/CT in Burkitt's lymphoma. Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248 [TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282 [TBL] [Abstract][Full Text] [Related]
8. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG. Tian J; Yang X; Yu L; Chen P; Xin J; Ma L; Feng H; Tan Y; Zhao Z; Wu W J Nucl Med; 2008 Feb; 49(2):186-94. PubMed ID: 18199618 [TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965 [TBL] [Abstract][Full Text] [Related]
10. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439 [TBL] [Abstract][Full Text] [Related]
11. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387 [TBL] [Abstract][Full Text] [Related]
12. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging]. Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892 [TBL] [Abstract][Full Text] [Related]
13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
14. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200 [TBL] [Abstract][Full Text] [Related]
15. F-18 FDG PET/CT in the management of thyroid cancer. Iagaru A; Kalinyak JE; McDougall IR Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020 [TBL] [Abstract][Full Text] [Related]
16. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer. Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269 [TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607 [TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT for staging of penile cancer. Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528 [TBL] [Abstract][Full Text] [Related]